ArticleNature genetics2019
Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.
Abstract readLetterComment
In one paragraph
Article in Nature genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.Nature genetics · 2026Article
- Multifaceted modeling of small intestinal neuroendocrine tumors.Endocrine oncology (Bristol, England) · 2024Review
- A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.Cancer discovery · 2023Article
- OncoLoop: A Network-Based Precision Cancer Medicine Framework.Cancer discovery · 2023Article
- Preclinical Models of Neuroendocrine Neoplasia.Cancers · 2022Review
- A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection.Communications biology · 2022Article
- A Model for Network-Based Identification and Pharmacological Targeting of Aberrant, Replication-Permissive Transcriptional Programs Induced by Viral Infection.Research square · 2022Article
- Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.Reviews in endocrine & metabolic disorders · 2021Review
- Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.Neoplasia (New York, N.Y.) · 2021Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
21 authors.
Mariano J AlvarezDepartment of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.
Pengrong YanChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-0021-6461
Mary L AlpaughChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0008-2718
Michaela BowdenDepartment of Translational Medicine, Bristol-Meyers Squibb, Boston, MA, USA.
Ewa SicinskaDepartment of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
Chensheng W ZhouDepartment of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
Charles KaranDepartment of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4012-8677
Ronald B RealubitDepartment of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.
Prabhjot S MundiDepartment of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.
Adina GrunnDepartment of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.
Dirk JägerMedical Oncology, National Center for Tumor Diseases Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
John A ChabotDepartment of Surgery, Columbia University Irvin Medical Center, New York, NY, USA.
Antonio T FojoHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Paul E ObersteinDepartment of Medical Oncology, Perlmutter Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5918-6004
Hanina HibshooshHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Jeffrey W MilsomColon and Rectal Surgery, Weill Cornell Medicine, New York, NY, USA.
Matthew H KulkeDepartment of Hematology and Medical Oncology, Boston University Cancer Center, Boston, MA, USA.
Massimo LodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Gabriela ChiosisChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diane L Reidy-LagunesDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andrea CalifanoDepartment of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA. califano@cumc.columbia.edu.ORCID http://orcid.org/0000-0003-4742-3679
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI CHIOSIS, GABRIELA · 2015 to 2019
$6.7MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MBiomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MA chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8MStorage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600kBiomarkers of response to Hsp90 inhibitors in triple-negative breast cancerR21CA158609 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2012 to 2013
$426kNCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA172546NCI NIH HHS R21 CA158609NCI NIH HHS R35 CA197745NCI NIH HHS U01 CA217858NIA NIH HHS R56 AG061869NIH HHS S10 OD012351NIH HHS S10 OD021764
Abstract
PubMed holds no abstract for this paper.
Indexed as
Neuroendocrine TumorsPrecision MedicineCell LineHumansMedical Oncology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.